Recently, the State Drug Administration approved the registration of "bio absorbable coronary rapamycin eluting stent system", an innovative product produced by Shandong Hua'an Biotechnology Co., Ltd。

The product is composed of stent and delivery system. The stent is composed of three parts: stent matrix, development mark and drug carrier coating. It can be used for the treatment of intravascular stenosis in patients with primary coronary atherosclerosis, improve the coronary blood flow of patients and prevent the occurrence of restenosis. The reference vessel diameter is 2.75mm-3.75mm, and the lesion length is ≤ 24mm。

Compared with the traditional metal drug stent, the product is expected to have the following advantages: 1. The final degradation products of the stent are water and carbon dioxide, which can reduce the problem of late thrombosis; 2. The stent is completely degraded and absorbed to reduce the long-term inflammatory reaction of foreign bodies; 3. It is compatible with MRI-CT, etc.; 4. It is convenient for stent intervention after the target disease becomes restenosis; 5. It is expected that the normal physiological function of target lesion vessels will also be obtained To partial recovery and improvement。

The drug supervision and administration department will strengthen the post marketing supervision of the product to protect the safety of patients with equipment。